Fate Therapeutics is a biopharmaceutical company. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. Co.'s other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. Co.'s allogeneic cellular immunotherapy pipeline include: ProTmune, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft. The FATE stock yearly return is shown above.
The yearly return on the FATE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FATE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|